arrow_back Back to App

Enhanced Transparency: Drug Manufacturer Reporting for Educational Transfers.

New rules aim to increase transparency in how drug manufacturers report expenses related to educational materials for healthcare professionals. This means citizens will have better insight into how pharmaceutical companies support medical education, potentially influencing trust in drug information.
Key points
Drug manufacturers must report expenses for educational materials like medical journals, textbooks, and conference reports.
The changes are intended to increase openness in the relationship between pharmaceutical companies and the medical community.
New reporting rules will apply to transfers of value made on or after the act's enactment date.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_4402
Sponsor: Rep. Burgess, Michael C. [R-TX-26]
Process start date: 2023-06-30
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

To amend title XI of the Social Security Act to clarify manufacturer transparency reporting requirements for certain transfers used for educational purposes.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_4402.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-06-30.

What are the main provisions?

Key points include:

  • Drug manufacturers must report expenses for educational materials like medical journals, textbooks, and conference reports.
  • The changes are intended to increase openness in the relationship between pharmaceutical companies and the medical community.
  • New reporting rules will apply to transfers of value made on or after the act's enactment date.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Burgess, Michael C. [R-TX-26].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health